A phase II study of high dose ARA-C and mitoxantrone for treatment of relapsed or refractory adult acute lymphoblastic leukemia
Peter J. Rosen(Providence Health & Services), Frederick R. Appelbaum(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Frederick W. Luthardt(University of Puget Sound), Cathryn Rankin(Cleveland Clinic), David R. Head(University of Southern California), David H. Boldt(The University of Texas at San Antonio Health Science Center), Reginald P. Pugh(Allegheny Health Network), Thomas H. Norwood(University of Washington), Chatchada Karanes(Erasmus MC Cancer Institute)
Cited by 20
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k